These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8109915)

  • 1. Biliary excretion of rufloxacin in humans.
    Privitera G; Nicastro G; Imbimbo BP; Cesana M; Visconti M; Lombardi F; Tagliabue G; Faleschini E; Colturani F; Franzini P
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2545-9. PubMed ID: 8109915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of rufloxacin in healthy volunteers after repeated oral doses.
    Mattina R; Bonfiglio G; Cocuzza CE; Gulisano G; Cesana M; Imbimbo BP
    Chemotherapy; 1991; 37(6):389-97. PubMed ID: 1662127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple-dose pharmacokinetics of rufloxacin in patients with cirrhosis.
    Triger DR; Granai F; Woodcock J; Wise R; Imbimbo BP
    Hepatology; 1993 Oct; 18(4):847-52. PubMed ID: 8406358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers.
    Kisicki JC; Griess RS; Ott CL; Cohen GM; McCormack RJ; Troetel WM; Imbimbo BP
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1296-301. PubMed ID: 1329618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of rufloxacin once daily in patients with lower respiratory tract infections.
    Rimoldi R; Fioretti M; Albrici A; Imbimbo BP
    Infection; 1992; 20(2):89-93. PubMed ID: 1316313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of rufloxacin in patients with impaired renal function.
    Perry G; Mant TG; Morrison PJ; Sacks S; Woodcook J; Wise R; Imbimbo BP
    Antimicrob Agents Chemother; 1993 Apr; 37(4):637-41. PubMed ID: 8388194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent.
    Wise R; Johnson J; O'Sullivan N; Andrews JM; Imbimbo BP
    J Antimicrob Chemother; 1991 Dec; 28(6):905-9. PubMed ID: 1667783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of rufloxacin in healthy volunteers.
    Segre G; Cerretani D; Moltoni L; Urso R
    Eur J Clin Pharmacol; 1992; 42(1):101-5. PubMed ID: 1311685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatobiliary elimination of temafloxacin.
    Sörgel F; Granneman GR; Mahr G; Kujath P; Fabian W; Nickel P
    Clin Pharmacokinet; 1992; 22 Suppl 1():33-42. PubMed ID: 1319869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-performance liquid chromatographic determination of rufloxacin and its main active metabolite in biological fluids.
    Lombardi F; Ardemagni R; Colzani V; Visconti M
    J Chromatogr; 1992 Apr; 576(1):129-34. PubMed ID: 1323570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers.
    Imbimbo BP; Broccali G; Cesana M; Crema F; Attardo-Parrinello G
    Antimicrob Agents Chemother; 1991 Feb; 35(2):390-3. PubMed ID: 2024974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and biliary elimination of temafloxacin in pigs.
    Jehl F; Bresler L; Koechlin C; Merle-Melet M; Didelot JP; Hazebroucq J
    J Antimicrob Chemother; 1992 Aug; 30(2):189-96. PubMed ID: 1328135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steady-state pharmacokinetics of rufloxacin in elderly patients with lower respiratory tract infections.
    Cogo R; Rimoldi R; Mattina R; Imbimbo BP
    Ther Drug Monit; 1992 Feb; 14(1):36-41. PubMed ID: 1312263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and metabolism of single oral doses of trovafloxacin.
    Vincent J; Teng R; Dalvie DK; Friedman HL
    Am J Surg; 1998 Dec; 176(6A Suppl):8S-13S. PubMed ID: 9935250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers.
    Aguilar L; Balcabao IP; Salvá P; Martín M; Costa J; Prieto J; Dal-ré R
    Antimicrob Agents Chemother; 1996 Jan; 40(1):17-21. PubMed ID: 8787872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites N-desmethylrufloxacin and rufloxacinsulfoxide in plasma and urine of humans.
    Vree TB; van den Biggelaar-Martea M; Imbimbo BP
    Eur J Drug Metab Pharmacokinet; 1992; 17(1):45-9. PubMed ID: 1323466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of single doses of rufloxacin on the disposition of theophylline and caffeine after single administration.
    Cesana M; Broccali G; Imbimbo BP; Crema A
    Int J Clin Pharmacol Ther Toxicol; 1991 Apr; 29(4):133-8. PubMed ID: 2071262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of magnesium-aluminum hydroxide antacid on absorption of rufloxacin.
    Lazzaroni M; Imbimbo BP; Bargiggia S; Sangaletti O; Dal Bo L; Broccali G; Bianchi Porro G
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2212-6. PubMed ID: 8257146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular pharmacokinetics of rufloxacin a new fluoroquinolone antibiotic.
    Nucci P; Lombardo N; Cremonesi F; Manitto MP; Brancato R; Ghione M
    Clin Ter; 1992 Jun; 140(6):563-7. PubMed ID: 1322259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group.
    Mattina R; Cocuzza CE; Cesana M
    Infection; 1993; 21(2):106-11. PubMed ID: 8387963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.